top of page
Milltrust Ventures News
Discover and stay ahead with the latest insights and news from the Milltrust Ventures’ ecosystem, which covers the thematic verticals of health, food security and sustainability.


52North raises £3.2 million to bring finger-prick cancer test closer to patients
52North, a University of Cambridge spin-out and a company that Milltrust Ventures invested in 2022 via the Future Health Fund, has raised £3.2 million in an early-stage funding round to accelerate clinical validation, regulatory progression and the UK launch of its lead product, Neutrocheck — a rapid, finger-prick blood test built to catch one of chemotherapy's most dangerous complications before it becomes an emergency. A test built to ease pressure on emergency care Neutroc
Milltrust International
Oct 32 min read


Oncoshot partners up with Mitsui & Co. Ltd. on Asia-US clinical data collaboration built on IHH's clinical data
We're proud to share that Oncoshot — a Milltrust Ventures portfolio company — has signed a service agreement with Mitsui & Co., Ltd. to deploy its AI platform across IHH Healthcare's hospital network. IHH runs 89 hospitals across 10 countries under brands including Gleneagles, Mount Elizabeth Hospitals, Singapore, Parkway Shenton Pte Ltd, and Fortis Healthcare — and Mitsui, its largest shareholder, is bringing Oncoshot in to standardise oncology data, shorten clinical trial t
Milltrust International
Sep 301 min read


Roslin Technologies is now an EIT Food RisingFoodStars 2026 Verified Scaleup
Roslin Technologies’ recognition as an EIT Food RisingFoodStars 2026 Verified Scaleup is an encouraging milestone and a strong example of why patient, early-stage capital matters. One of Milltrust’s longstanding priorities has been to support science-led companies from their earliest stages. In 2016, Milltrust backed Roslin Technologies through a £10 million seed investment, which became one of the first investments of the British Innovation Fund. The fund was established to
Milltrust International
Jul 231 min read


Jiva.AI and Aevice Health partner to pioneer breakthrough medical AI for Asthma adverse event prediction using AeviceMD
Jiva.AI and Aevice Health develop AI model to predict asthma attacks up to 72 hours in advance For the more than 545 million people living with chronic respiratory disease worldwide, an asthma attack can arrive without warning — a sudden deterioration that, caught late, ends in an emergency room. Jiva.AI and Aevice Health have spent three years working to change that, completing a joint programme that produced an AI model capable of predicting asthma exacerbations within 24,
Milltrust International
Jun 302 min read


Strategic partnership struck between Attomarker and EpitogenX
Attomarker, a spinout from the University of Exeter, has signed a co-development agreement with EpitogenX to advance precision immunology diagnostics across multiple diseases, starting from Lyme Disease and Long Lyme. This partnership helps to unite both companies’ complementary strengths in next-generation antigen engineering and multiplex immunological diagnostics. The objective is to accelerate the development and commercialisation of a new class of precision diagnostics b
Milltrust International
Feb 172 min read


Curie Oncology partners up with Oncoshot to deploy AI in improving patient outcomes in Asia, makes strategic investment into the company
Curie Oncology, one of Southeast Asia’s fastest growing private oncology networks that runs numerous clinical trials across Singapore and Malaysia, has partnered with Singapore-based healthtech company Oncoshot to deploy AI-powered clinical research tools that can rapidly structure and analyse clinical data, enabling oncologists and research teams to identify eligible patients sooner and help patients gain faster access to ongoing clinical trials more efficiently. AI as an
Milltrust International
Dec 15, 20252 min read
bottom of page
